Axsome Therapeutics Files Q1 2025 10-Q

Ticker: AXSM · Form: 10-Q · Filed: May 5, 2025 · CIK: 1579428

Axsome Therapeutics, INC. 10-Q Filing Summary
FieldDetail
CompanyAxsome Therapeutics, INC. (AXSM)
Form Type10-Q
Filed DateMay 5, 2025
Risk Levelmedium
Sentimentneutral

Sentiment: neutral

Topics: 10-Q, financials, pharmaceutical

Related Tickers: AXSM

TL;DR

AXSM Q1 2025 10-Q is in. Check financials.

AI Summary

Axsome Therapeutics, Inc. filed its 10-Q for the period ending March 31, 2025. The company's financial statements reflect its ongoing operations and financial position. Key financial data and disclosures are provided for investors and stakeholders.

Why It Matters

This filing provides crucial financial and operational updates for Axsome Therapeutics, Inc., offering insights into the company's performance and financial health for the first quarter of 2025.

Risk Assessment

Risk Level: medium — As a pharmaceutical company, Axsome Therapeutics faces inherent risks related to drug development, regulatory approvals, and market competition, which are detailed in their SEC filings.

Key Numbers

Key Players & Entities

FAQ

What is the reporting period for this 10-Q filing?

The Conformed Period of Report is 20250331, indicating the filing covers the period ending March 31, 2025.

When was this 10-Q filed with the SEC?

This 10-Q was filed on 20250505.

What is Axsome Therapeutics, Inc.'s Standard Industrial Classification code?

The SIC code for Axsome Therapeutics, Inc. is 2834, which corresponds to Pharmaceutical Preparations.

Where is Axsome Therapeutics, Inc. headquartered?

The company's business and mailing address is One World Trade Center, 29th Floor, New York, NY 10007.

What is the SEC file number for Axsome Therapeutics, Inc.?

The SEC File Number for Axsome Therapeutics, Inc. is 001-37635.

Filing Details

This Form 10-Q (Form 10-Q) was filed with the SEC on May 5, 2025 regarding Axsome Therapeutics, Inc. (AXSM).

View full filing on EDGAR

View Full Filing

View this 10-Q filing on SEC EDGAR

View on Read The Filing